Evidence map›Paper›PMID 39125669›Full record

ArticleInternational journal of molecular sciences2024

Theranostics Using MCM-41-Based Mesoporous Silica Nanoparticles: Integrating Magnetic Resonance Imaging and Novel Chemotherapy for Breast Cancer Treatment.

Indira C B Pires, Samia I Shuchi, Braulio de V A Tostes, Dayane K D do N Santos, William L Burnett, Burke C Leonce, Omar R Harvey, Jeffery L Coffer, Idio Alves de Sousa Filho, Petrônio Filgueiras de Athayde-Filho and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Indira C B PiresDepartment of Chemistry, Federal University of Pernambuco, Recife 50670-901, PE, Brazil.
Samia I ShuchiSchool of Biomedical Sciences, Departments of Microbiology, Immunology, and Genetics and Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Braulio de V A TostesDepartment of Chemistry, Federal University of Pernambuco, Recife 50670-901, PE, Brazil.ORCID 0009-0004-1183-5270
Dayane K D do N SantosDepartment of Chemistry, Federal University of Pernambuco, Recife 50670-901, PE, Brazil.
William L BurnettDepartment of Chemistry and Biochemistry, Texas Christian University, Fort Worth, TX 76109, USA.
Burke C LeonceDepartment of Chemistry and Biochemistry, Texas Christian University, Fort Worth, TX 76109, USA.
Omar R HarveyDepartment of Chemistry and Biochemistry, Texas Christian University, Fort Worth, TX 76109, USA.ORCID 0000-0002-6604-7237
Jeffery L CofferDepartment of Chemistry and Biochemistry, Texas Christian University, Fort Worth, TX 76109, USA.ORCID 0000-0003-0267-9646
Idio Alves de Sousa FilhoInstitute of Chemistry, Federal Rural University of Rio de Janeiro, Rio de Janeiro 23890-000, RJ, Brazil.
Petrônio Filgueiras de Athayde-FilhoDepartment of Chemistry, Federal University of João Pessoa, João Pessoa 58051-900, PB, Brazil.
Severino A JuniorDepartment of Chemistry, Federal University of Pernambuco, Recife 50670-901, PE, Brazil.
J Michael MathisSchool of Biomedical Sciences, Departments of Microbiology, Immunology, and Genetics and Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.ORCID 0000-0001-5528-5195

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 200600/2022-2Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco IBPG-0326-1.06/21University of North Texas Health Science Center bridge funding
6 · The paper itself

Abstract

Advanced breast cancer remains a significant oncological challenge, requiring new approaches to improve clinical outcomes. This study investigated an innovative theranostic agent using the MCM-41-NH

Indexed as

Breast NeoplasmsMagnetic Resonance ImagingNanoparticlesSilicon DioxideTheranostic NanomedicineAnimalsAntineoplastic AgentsCell Line, TumorContrast MediaFemaleGadoliniumHumansMicePorosityXenograft Model Antitumor AssaysAntineoplastic AgentsContrast MediaGadoliniumMCM-41Silicon Dioxidebreast cancercontrast agentgadoliniumMCM-41mesoporous silica nanoparticleMIH 2.4BlMRItheranostics

Identifiers

PMID39125669
PMCPMC11311303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.